Patients suffering from a rare disorder previously were able to obtain the treatment for free from a small pharmaceutical company that offered it through an FDA program called “compassionate use.” In November, the FDA allowed Catalyst to distribute the drug, with exclusive rights to market it. The following month the company said it would sell Firdapse for $375,000 a year. In other news, lawmakers are inviting CEOs from seven major drug companies to testify on prices.
from Kaiser Health News http://bit.ly/2S98XuS
February 05, 2019
Rose
Health News, Kaiser Health News
No comments
Related Posts:
Mystery Deepens Over Head Injuries Of U.S. Diplomats In CubaThe diplomats showed signs of a concussion, though they received no blows to the head. Experts are stumped on what happened. from Kaiser Health News http://ift.tt/2CpfrsO … Read More
State Highlights: Doctor Files Whistleblower Suit Against D.C.’s Public Hospital; N.C., Minn. Officials Report Rise In Vaping Among TeensMedia outlets report on news from D.C., North Carolina, Minnesota, California, Connecticut, Illinois, Michigan and Wisconsin. from Kaiser Health News http://ift.tt/2Cpfuou … Read More
A Single Pharmacy In A Tiny West Virginia Town Was Shipped 12.3 Million Doses Of Opioids Over 8-Year PeriodThe House Energy and Commerce Committee has launched an investigation into how that slipped by regulators' attention. News on the opioid crisis comes out of Maryland, Pennsylvania and Arizona, as well. from Kaiser Health New… Read More
Flashy Improvements Are Turning Gene-Editing Technology Into Swiss Army Knife Of TreatmentsScientists were already excited about CRISPR's potential as a total game-changer in curing illnesses, and now it's been taken up another level. In other public health news: stem cells, gut bacteria, neighborhoods' effects on … Read More
Research Roundup: Kidney Disease; Bariatric Surgery Outcomes; Medicare Wellness VisitsEach week, KHN compiles a selection of recently released health policy studies and briefs. from Kaiser Health News http://ift.tt/2EyqZjs … Read More
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment